X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-13 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.59 | +167,654 | 15,578,732 | +1% | +$2,278,811 | |||||
| M | 2025-01-08 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.21 | +225,119 | 15,411,078 | +1% | +$2,974,819 | |||||
| D | 2025-01-06 | ZYME | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $14.92 | -21,200 | 23,333 | -48% | -$316,391 | |||||
| D | 2025-01-06 | ZYME | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $14.92 | -57,291 | 80,803 | -41% | -$855,017 | |||||
| D | 2025-01-06 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Officer | S - Sale+OE | $14.92 | -11,110 | 8,890 | -56% | -$165,807 | |||||
| M | 2024-12-30 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $14.64 | +363,369 | 15,185,959 | +2% | +$5,321,176 | |||||
| M | 2024-12-24 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $14.44 | +130,309 | 14,822,590 | +1% | +$1,882,115 | |||||
| AM | 2024-12-19 | ZYME | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.98 | +1,254,808 | 14,692,281 | +9% | +$17,544,284 | |||||
| DM | 2024-01-05 | ZYME | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $10.79 | -23,904 | 23,762 | -50% | -$257,845 | |||||
| DM | 2024-01-05 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $10.79 | -5,994 | 6,503 | -48% | -$64,656 | |||||
| DM | 2024-01-05 | ZYME | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $10.79 | -9,799 | 7,367 | -57% | -$105,699 | |||||
| D | 2023-12-11 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $9.13 | -886 | 1,997 | -31% | -$8,089 | |||||
2023-06-16 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $8.12 | +3,350,000 | 13,437,473 | +33% | +$27,202,000 | ||||||
2023-03-28 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $8.00 | +200,000 | 10,087,473 | +2% | +$1,600,000 | ||||||
| D | 2023-03-10 | ZYME | Klompas Neil A | Pres, COO | S - Sale+OE | $7.83 | -2,977 | 17,732 | -14% | -$23,298 | |||||
| M | 2023-01-19 | ZYME | Ecor1 Capital, LLC | 10% | P - Purchase | $9.70 | +307,500 | 9,887,473 | +3% | +$2,982,733 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |